Comparison of regularly scheduled with as-needed use of albuterol in mild asthma

New England Journal of Medicine

Volumn 335, Issue 12, 1996, Pages 841-847

  Drazen, Jeffrey M ^a   Israel, Elliot ^a   Boushey, Homer A ^b   Chinchilli, Vernon M ^c   Fahy, John V ^b   Fish, James E ^d   Lazarus, Stephen C ^b   Lemanske, Robert F ^e   Martin, Richard J ^f   Peters, Stephen P ^d   Sorkness, Christine ^e   Szefler, Stanley J ^f   Cherniak, Reuben ^f   Hurd, Suzanne ^g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^g NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SALBUTAMOL;

ADULT; ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ASTHMA; CHILD; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; TREATMENT OUTCOME;

EID: 9544253883     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199609193351202     Document Type: Article

References (40)

1. Grain EF, Weiss KB, Bijur PE, Hersh M, Westbrook L, Stein RE. An estimate of the prevalence of asthma and wheezing among inner-city children. Pediatrics 1994;94:356-62.
2. Auerbach I, Springer C, Godfrey S. Total population survey of the frequency and severity of asthma in 17 year old boys in an urban area in Israel. Thorax 1993;48:139-41.
3. National Asthma Education Program. Executive summary: guidelines for the diagnosis and management of asthma. Bethesda, Md.: National Institutes of Health, 1994. (Publication no. 94-3042A.)
4. Guidelines for the management of asthma: a summary. BMJ 1993;306: 776-82.
5. Drugs for asthma. Med Lett Drugs Ther 1987;29:11-6.
6. Howell JBL. Asthma: acute reversible airway obstruction. In: Beeson PB, McDermott W, eds. Textbook of medicine. 14th ed. Philadelphia: W.B. Saunders, 1975:825-30.
7. Stauffer JL. Disorders of the airway. In: Schroeder SA, Krupp MA, Tierney LM Jr, McPhee SJ, eds. Current medical diagnosis & treatment 1989. Norwalk, Conn.: Appleton & Lange, 1989:135-41.
8. Woolcock AJ. Asthma. In: Murray JF, Nadel JA, eds. Textbook of respiratory medicine. Philadelphia: W.B. Saunders, 1988:1030-68.
9. Shepherd GL, Hetzel MR, Clark TJ. Regular versus symptomatic aerosol bronchodilator treatment of asthma. Br J Dis Chest 1981;75:215-7.
10. Zellweger JP, Clottu R, Crittin A, et al. Etude comparée effets de Pinhalation de salbutamol régulièrement ou à la demande dans le traitement de Pasthme. Schweiz Med Wochenschr 1986;116:1260-3.
11. Repsher LH, Anderson JA, Bush RK, et al. Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol. Chest 1984;85:34-8.
12. Harvey JE, Tattersfield AE. Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects. Thorax 1982;37:280-7.
13. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992;327:1420-5.
14. Chapman KR, Kesten S, Szalai JP. Regular vs as-needed inhaled salbutamol in asthma control. Lancet 1994;343:1379-82.
15. Scars MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336:1391-6.
16. Taylor DR, Sears MR, Herbison GP, et al. Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax 1993;48: 134-8.
17. Spitzer WO, Suissa S, Ernst P, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-6.
18. Dompeling E, van Schayek CP, van Grunsven PM, et al. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids: a 4-year prospective study. Ann Intern Med 1993;118:770-8.
19. Cockcroft DW, Obyrne PM, Swystun VA, Bhagat R. Regular use of inhaled albuterol and the allergen-induced late asthmatic response. J Allergy Clin Immunol 1995;96:44-9.
20. Nelson HS, Szefler SJ, Martin RJ. Regular inhaled beta-adrenergic agonists in the treatment of bronchial asthma: beneficial or detrimental? Am Rev Respir Dis 1991;144:249-50.
21. Twentyman OP, Higenbottam TW. Controversies in respiratory medicine: regular inhaled beta-agonists - clear clinical benefit or a hazard to health? 1. Beta-agonists can be used safely and beneficially in asthma. Respir Med 1992;86:471-6.
22. 2 agonists in asthma: much ado about nothing? Adverse effects are not proved. BMJ 1994;309:795-6.
23. 2 agonists in asthma: much ado about nothing? Still cause for concern. BMJ 1994;309:794-5.
24. Crane J, Pearce N, Burgess C, Beasley R. Asthma and the beta agonist debate. Thorax 1995;50:Suppl 1:S5-S10.
25. Wanner A. Is the routine use of inhaled beta-adrenergic agonists appropriate in asthma treatment? Yes. Am J Respir Crit Care Med 1995;151: 597-9.
26. Sears MR. Is the routine use of inhaled beta-adrenergic agonists appropriate in asthma treatment? No. Am J Respir Crit Care Med 1995;151: 600-1.
27. Taylor DR, Sears MR, Regular beta-adrenergic agonists: evidence, not reassurance, is what is needed. Chest 1994;106:552-9.
28. McFadden FR Jr. Perspectives in beta 2-agonist therapy: vox clamantis in deserto vel lux in tenebris? J Allergy Clin Immunol 1995;95:641-51.
29. Nelson HS. β-Adrenergic bronchodilators. N Engl J Med 1995;333: 499-506.
30. Barrett TF, Strom BL. Inhaled beta-adrenergic receptor agonists in asthma: more harm than good? Am J Respir Crit Care Med 1995;151:574-7.
31. Giuntini CG, Paggiaro PL. Present state of the controversy about regular inhaled beta-agonists in asthma. Eur Respir J 1995;8:673-8.
32. Page C, Costello J. Controversies in respiratory medicine: regular inhaled beta-agonists - clear clinical benefit or a hazard to health? 2. Why beta-agonists should not be used regularly. Respir Med 1992;86:477-9.
33. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47: 76-83.
34. Tashkin DP, Altose MD, Bleecker ER, et al. The Lung Health Study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. Am Rev Respir Dis 1992;145:301-10.
35. Vonesh EF, Carter RL. Efficient inference for random-coefficient growth curve models with unbalanced data. Biometrics 1987;43:617-28.
36. Laird NM, Donnelly C, Ware JH. Longitudinal studies with continuous responses. Stat Methods Med Res 1992;1:225-47.
37. Pocock SJ, Interim analyses for randomized clinical trials: the group sequential approach. Biometrics 1982;38:153-62.
38. Geller NL, Pocock SJ. Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. Biometrics 1987;43: 213-23.
39. Martin RJ, Cicutto LC, Smith HR, Ballard RD, Szefler SJ, Airways inflammation in nocturnal asthma. Am Rev Respir Dis 1991;143:351-7.
40. Global initiative for asthma: global strategy for asthma management and prevention: NHLBI/WHO workshop report. Bethesda, Md.: National Heart, Lung, and Blood Institute, 1995. (NIH publication no. 95-3659.)